Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Total Liabilities (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Total Liabilities for 16 consecutive years, with $16.5 million as the latest value for Q1 2026.

  • Quarterly Total Liabilities rose 360.3% to $16.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $16.5 million through Jan 2026, up 360.3% year-over-year, with the annual reading at $3.3 million for FY2025, 83.93% down from the prior year.
  • Total Liabilities for Q1 2026 was $16.5 million at PharmaCyte Biotech, down from $19.4 million in the prior quarter.
  • The five-year high for Total Liabilities was $22.5 million in Q1 2024, with the low at $586581.0 in Q2 2023.
  • Average Total Liabilities over 5 years is $9.5 million, with a median of $3.6 million recorded in 2025.
  • The sharpest move saw Total Liabilities surged 3375.95% in 2024, then plummeted 91.15% in 2025.
  • Over 5 years, Total Liabilities stood at $1.3 million in 2022, then surged by 1487.38% to $20.8 million in 2023, then tumbled by 44.04% to $11.6 million in 2024, then soared by 66.76% to $19.4 million in 2025, then dropped by 15.19% to $16.5 million in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $16.5 million, $19.4 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.